# RTOG 0924 (NCT01368588)

> Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

No report yet. It can be ordered.

- Indication: unfavorable intermediate or favorable high risk prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01368588
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Radiation Therapy Oncology Group
- Conditions: Prostate Cancer
- Interventions: three-dimensional conformal radiotherapy; intensity modulated radiotherapy; Brachytherapy; Anti-androgen; luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
- Enrollment: 2590
- Primary outcome: Percentage of Participants Alive (Overall Survival)

## Indexed commentary on RTOG 0924 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 28 posts on X
- 2 podcast episodes
- 1 YouTube video
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rtog-0924-nct01368588

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01368588", "email": "<work email>"}; the inbox owner confirms by the emailed link.